We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EUROB:ATHEXEUROBANK S.A. Analysis

Data as of 2026-05-27 - not real-time

€3.97

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Eurobank S.A. is trading at €3.97, comfortably above its 20‑day (€3.78), 50‑day (€3.69) and 200‑day (€3.56) simple moving averages, and the MACD histogram is positive with a bullish signal line, indicating momentum is still in the buyer’s camp. The RSI sits at 57.7, suggesting the stock is not overbought, while the 30‑day volatility of 46.5% and a decreasing volume trend temper the rally. With a current price near the midpoint of its support (€3.50) and resistance (€4.02) band, the model‑based upside of roughly 20% to a target of €4.76 appears achievable, though the high volatility and thinning volume warrant caution.
Fundamentally, Eurobank looks undervalued – its trailing P/E of 10.7 is well below the industry average of 16.7 and the price‑to‑book of 1.32 reflects a modest premium to book value. The bank posted a profit margin of 44.8% and a ROE of 13.7%, with revenue growing 8.5% YoY and Q1 FY2026 net profit of €351 million. A dividend yield of 3.02% paid at a 41% payout ratio, coupled with a strong cash buffer (€13.7 bn) against €11.9 bn debt, underpins the sustainability of shareholder returns. Analyst consensus is a “strong buy” with a median price target of €4.75, reinforcing the case for upside potential.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD and price above all key SMAs
  • Attractive upside to target price with support intact
  • Moderate volatility but low beta reduces market risk

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued valuation metrics relative to peers
  • Solid dividend yield and sustainable payout
  • Strong earnings growth and improving profitability

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Low beta and stable cash generation support long‑term stability
  • Consistent dividend policy provides income stream
  • Strategic regional presence and expanding asset base

Key Metrics & Analysis

Financial Health

Revenue Growth8.50%
Profit Margin44.79%
P/E Ratio10.7
ROE13.68%
ROA1.31%
P/B Ratio1.3
Op. Cash Flow€-1895000064
Industry P/E16.7

Technical Analysis

TrendBullish
RSI57.7
Support€3.50
Resistance€4.02
MA 20€3.78
MA 50€3.69
MA 200€3.56
MACDBullish
VolumeDecreasing
Fear & Greed Index91.13

Valuation

Target Price€4.76
Upside/Downside19.80%
GradeUndervalued
TypeBlend
Dividend Yield3.02%

Risk Assessment

Beta0.49
Volatility46.53%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.